GSK’s Blenrep Faces Constrained Market Prospects Due To Regulatory And Competitive Challenges
Pharmaceuticals / United Kingdom / Tue 12 Mar, 2024
Key View
- GSK’s latest Blenrep (belantamab mafodotin) trial results will improve the drug’s outlook as a potential multiple myeloma drug treatment, but recent regulatory challenges cast doubt over a potential market re-entry.
- Due to a highly competitive multiple myeloma drug market companies will continue seeking label expansions in earlier